Some good news
Long-term follow up of a phase 1/2 study ... - Cure Parkinson's
Long-term follow up of a phase 1/2 study of ProSavin, a lentiviral vector gene therapy for Parkinson’s disease
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Out of 15 patients, " Ninety-six drug-related adverse events were reported (87 mild, 6 moderate, 3 severe) of which more than half occurred in the first year. The most common drug-related events were dyskinesias (33 events, 11 patients) and on-off phenomena (22 events, 11 patients)." Also, apparently subsequent to this therapy, "Eight patients received deep brain stimulation at different time points and their subsequent assessments continued to assess safety." So for least those eight out of the 15, the gene therapy was not sufficient.
Not what you're looking for?
You may also like...
Potential disease-modifying therapy enters Phase 2
disease.\\"
------------------------------------
https://youtu.be/aQfvVEXgmfc
Light Therapy for Parkinson’s Disease
light therapy information together in one place:...
Electroconvulsive Therapy Intervention for Parkinson’s Disease
Electroconvulsive Therapy Intervention for Parkinson’s Disease...
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
samples accounting for placebo....